Spero Therapeutics, Inc. (SPRO) Stock Price, Quote & News - Stock Analysis (2024)

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024 Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024 Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDRGram-negative Bacterial Infections Spero Therapeutics to Present at Cowen's 44th Annual Healthcare Conference Spero Therapeutics Provides Corporate Update and 2024 Outlook Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO TrialEvaluating Tebipenem HBr in Complicated Urinary Tract Infections Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023 SPERO ALERT: Bragar Eagel & Squire, P.C. is Investigating Spero Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Spero Therapeutics, Inc. (NASDAQ: SPRO) for Potential Breaches of Fiduciary Duty By Its Board of Directors Spero Therapeutics to Present at Cantor's Global Healthcare 2023 Investor Conference Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference Spero Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023 Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr Spero Therapeutics Appoints Sath Shukla as President & Chief Executive Officer Spero Therapeutics Announces First Quarter 2023 Operating Results and Provides a Business Update Spero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023 Spero Therapeutics to Present at Upcoming Investor Conference Spero Therapeutics to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases Spero Therapeutics Announces Fourth Quarter and Full Year 2022 Operating Results and Provides Business Update